We release a wide range of research, guidance and statistical publications.

Publications released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.

Showing 3005 results

  • Recognising and responding to an overdose

    • 09 May 2024
    • Guidance
    Depressant drug overdose signs  unresponsive (will not wake when shaken) snoring or noisy breathing seizures or fits nausea and vomiting blue or pale lips and skin pin-point...
  • Actions for drug and alcohol service staff

    • 09 May 2024
    • Guidance
    Services, and Alcohol and Drug Partnerships should share this alert with local partners who are likely to be in contact with people who take drugs. When asking patients about...
  • Actions for emergency service, clinical and healthcare staff

    • 09 May 2024
    • Guidance
    Staff working in emergency services and healthcare should be vigilant for the presentation of xylazine toxicity, particularly when working with patients who have used opioids, are...
  • Recommendations

    • 09 May 2024
    • Guidance
    The presence of xylazine as an adulterant in heroin, benzodiazepines, counterfeit pharmaceuticals and in THC vapes indicates widespread availability. Emergency care staff...
  • Legal status

    • 09 May 2024
    • Guidance
    In the UK, the supply and importation of xylazine is controlled by the Psychoactive Substances Act 2016. In February 2024, the Advisory Council on the Misuse of Drugs (ACMD)...
  • RADAR Xylazine 2024

    • 09 May 2024
    • Guidance
    • Drugs

    RADAR publishes ad-hoc alerts related to new trends, drugs and harms. Alert 2024/09 was published on 9 May 2024, due to an increase in detections of xylazine in the unregulated drugs market.

  • RADAR alert 2024/09 - increase in the detection of xylazine

    • 09 May 2024
    • Report
    • Drugs
    RADAR alert 2024/09 - increase in the detection of xylazine...
  • Xylazine

    • 09 May 2024
    • Guidance
    Xylazine is a depressant that can cause drowsiness, low heart rate and low blood pressure. It is an alpha-2-adrenoceptor (a2) agonist. It binds to a2 receptors in the body causing...
  • Wound care

    • 09 May 2024
    • Guidance
    The mechanism by which xylazine causes wound damage is not well understood. Xylazine can cause blood vessels to narrow and reduce the blood supply to the skin which can slow down...
  • Actions for high-risk settings

    • 09 May 2024
    • Guidance
    High-risk settings are places where people may take more drugs than average, often at the same time and from shared batches. Places at higher risk include prisons, hostels,...